Novartis UK Selects Captiva's InputAccel for Invoices; Company to Streamline Invoice Processing, Speed Payments to Suppliers

Captiva Software Corporation (NASDAQ:CPTV), a leading
provider of input management solutions, today announced that Novartis
UK, the British affiliate of Novartis AG, a world leader in the
research and development of products to protect and improve health and
well being, has selected Captiva's InputAccel for Invoices(TM) to
capture and process invoices more efficiently and speed payment to
suppliers.
   InputAccel for Invoices' intelligent document recognition and
line-item capture capabilities enable Novartis to accurately and
efficiently process its often complex invoices without the need to
create templates for each supplier. After capturing the pertinent
data, InputAccel for Invoices exports invoice information and images
into the company's SAP financial system for streamlined processing,
storage and retrieval. Novartis selected InputAccel for Invoices in
part because of its SAP certification, ensuring seamless integration
with the company's legacy accounting system. In addition, Novartis
chose the solution because it is built on InputAccel(R), Captiva's
award-winning document capture software, which Novartis is considering
for use in other departments throughout the company to capture
clinical trial, customer service and human resources documents.
   "Novartis desired an automated invoice capture solution that is
flexible enough to grow with the company's future needs," said Daniel
Vaniche, Captiva's Vice President of Field Sales and Operations in
Europe, Middle East and Africa (EMEA). "We're pleased to provide a
solution that not only meets Novartis' current needs, but is also
scalable enough to meet the company's future needs as it expands
document capture to its other business units."
   Built on InputAccel and utilizing capabilities from FormWare(R),
InputAccel for Invoices enables companies to process invoices more
efficiently and accurately, reduce turnaround times for payment, take
advantage of early payment discounts and to easily access captured
invoice images and electronic data.

   About Novartis UK

   Novartis UK is the British affiliate of Novartis AG. Headquartered
in Basel, Switzerland, Novartis AG is a world leader in
pharmaceuticals and consumer health. Last year, the Group's businesses
achieved sales of $28.2 billion (US), net income of $5.8 billion (US)
and invested approximately $4.2 billion (US) in research and
development. Novartis Group companies employ more than 80,000 people
and operate in over 140 countries around the world. Further
information about Novartis UK is available at www.novartis.co.uk.

   About Captiva Software Corporation

   Captiva Software Corporation (NASDAQ:CPTV) is a leading provider
of input management software solutions. Since 1989, the company's
award-winning products have been used to manage business critical
information from paper, faxed and scanned forms and documents,
Internet forms and XML data streams into the enterprise in a more
accurate, timely and cost-effective manner. These products automate
the processing of billions of forms and documents annually, converting
their contents into information that is usable in database, document,
content and other information management systems. Captiva's technology
serves thousands of users in insurance, financial services,
government, business process outsourcing, direct marketing and other
markets. For more information, visit www.captivasoftware.com.

   InputAccel for Invoices is a trademark, and InputAccel and
FormWare are registered trademarks of Captiva Software Corporation.
All other trademarks or registered trademarks are the property of
their respective owners.

   This press release may contain forward-looking statements that
involve risks and uncertainties, as well as assumptions that, if they
prove incorrect, could cause our results to differ materially from
those expressed or implied by such forward-looking statements. All
statements other than statements of historical fact are statements
that could be deemed forward-looking statements, including, among
other things, any projections of earnings, revenues (including where
the underlying contract has already been signed), or other financial
items; any statements of the plans, strategies, and objectives of
management for future operations; any statements concerning proposed
new products, services, or developments; any statements regarding
future economic conditions or performance; statements of belief and
any statement of assumptions underlying any of the foregoing. The
risks, uncertainties and assumptions referred to above include, among
other things, performance of contracts by customers and partners;
employee management issues; the timely development, production and
acceptance of products and services and their feature sets; the
challenge of managing asset levels, including inventory; the flow of
products into third-party distribution channels; and the difficulty of
keeping expense growth at modest levels while increasing revenues.
Announcements of contract awards should not be interpreted as
reflecting revenue in any particular period and may relate to revenue
recorded in prior periods. These and other risks and factors that
could cause events or our results to differ from those expressed or
implied by such forward-looking statements are described in our most
recent annual report on Form 10-K and quarterly reports on Form 10-Q,
as well as other subsequent filings with the Securities and Exchange
Commission. We assume no obligation and do not intend to update these
forward-looking statements.